TrialRheumatology (Oxford, England)2023

Efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis: a post-hoc analysis of a randomized phase III trial.

Arnaud Constantin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.